Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease
Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease
New perceptions about handling and patient satisfaction of the everyday use of Berodual®
 Respimat® in patients with chronic obstructive lung disease (COLD). Moreover, further
 knowledge should be attained about the tolerability of Berodual® Respimat®
Inclusion Criteria:

 -  Male and female patients aged at least 18 years who were suffering from symptoms of a
 COLD (naive or pre-treated) could be included in the PMS

 Exclusion Criteria:

 -  Patients who meet one or more of the general or specific contraindications mentioned
 in the Summary of Product Characteristics (SmPC) are excluded from the Postmarketing
 Surveillance (PMS)